Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDORSE: gliclazide MR versus rosiglitazone added to metformin in type 2 diabetes
ISRCTN67790431Phase 3Terminated
- Sponsor
- Servier
- Start
- Nov 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Gliclazide MR + metformin with Rosiglitazone + metformin (2 arms). Primary endpoint: Change in HbA1c. Started Nov 2006; status: terminated.
02
Drugs
gliclaziderosiglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN67790431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN67790431.